Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer

By sjmartinez • October 15, 2024

Bang YH, Lee CK, Bang K, Kim HD, Kim KP, Jeong JH, Park I, Ryoo BY, Lee DK, Choi HJ, Chung T, Jeon SH, Shin EC, Oum C, Kim S, Lim Y, Park G, Ahn CH, Lee T, Finn RS, Ock CY, Shin J, Yoo C. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer. Clin Cancer Res. 2024 Oct 15;30(20):4635-4643. doi: 10.1158/1078-0432.CCR-24-1265. PMID: 39150517.

Tags: Hematology/Oncology, Publications

A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer

Finn RS, Rugo HS, Cortes J, Loibl S, Foley G, Gauthier E, Wang Y, Kim S, Anders L, Slamon DJ. A Decade After Approval of[...]

Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]

Garassino MC, Gadgeel S, Novello S, Halmos B, Felip E, Speranza G, Hui R, Garon EB, Horinouchi H, Sugawara S, Rodriguez-Abreu D, Reck M, Cristescu[...]

Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung cancer

Chan AA, Sankar K, Reckamp KL, Díaz B, Lee DJ. Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung[...]